Should You Buy AstraZeneca plc, WH Smith Plc & De La Rue plc Today?

Royston Wild considers the investment case for AstraZeneca plc (LON: AZN), WH Smith Plc (LON: SMWH) and De La Rue plc (LON: DLAR).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m running the rule over three recent headline makers.

Book beauty

Stationery and magazines giant WH Smith (LSE: SMWH) has fallen 3% following its latest trading update released today. But I view this as nothing more than profit-taking following the share’s steady price ascent.

The retailer — which recently struck record peaks of 1,878p per share — advised that pre-tax profit surged 11% in the six months to February, to £80m. Although like-for-like sales at its High Street division were flat, this represented WH Smith’s best performance for years.

The impact of massive cost-cutting, coupled with huge investment in new products in recent years, is clearly paying off handsomely. And I reckon the stationer’s rolling store expansion scheme should also keep profits heading higher in the years ahead.

This view is shared by the City, and WH Smith is expected to print earnings rises of 7% and 8% for the years to August 2016 and 2017, respectively. I reckon subsequent P/E ratings of 19.2 times and 18 times are fair value given the exceptional progress of WH Smith’s turnaround strategy.

Time to cash out?

Like WH Smith, De La Rue (LSE: DLAR) also released bubbly trading numbers in midweek trading. But these better-than-expected results drove shares in the cash printer 10% higher from Tuesday’s close.

De La Rue announced that revenue for the period to March 2016 had been in line with expectations, adding that full-year underlying operating profit is now expected to ring in at £62m, beating its previous estimates. The company attributed this upgrade to the “strong operational outperformance on certain contracts within our Currency business.”

Despite today’s positive news, however, I believe that De La Rue remains a risky selection for stock pickers thanks to the impact of rising competition, and the potential for increasing revenue troubles in an increasingly ‘cashless’ world.

The City expects De La Rue to bounce from a 27% earnings slip in fiscal 2016 with an 11% bump next year. Some would argue that low P/E ratings of 13.2 times and 11.7 times fairly reflect the risks facing the money-maker. But I reckon the huge structural issues facing the firm still make it an unattractive stock selection.

Sales outlook still improving

A string of positive testing news has boosted the revenues picture for drugs giant AstraZeneca (LSE: AZN) in recent days.

The Cambridge firm received positive news yesterday after Clovis Oncology‘s lung cancer battler Rociletinib had been shot down by the US Food and Drug Administration. The news paves the way for AstraZeneca’s own Tagrisso treatment to dominate the market, the drug having received approval in the autumn.

AstraZeneca’s renewed efforts to rejuvenate its product pipeline are clearly producing the goods, with it also announcing this week that its Alzheimer’s product designed with Eli Lilly will proceed to Phase III testing.

Sure, the issue of patent expirations on key drugs is expected to keep earnings under pressure for some time yet — bottom line dips of 7% and 1% are currently pencilled-in by the City for 2016 and 2017, respectively. Still, I reckon consequent P/E ratios of 14.8 times and 15 times represent terrific entry points to get on board AstraZeneca’s ever-improving long-term outlook.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »